The UK Medicines and Healthcare products Regulatory Agency (MHRA) has released a review assessing the benefit-risk profile of avacopan, a medicine indicated for use in some rare autoimmune diseases that affect small blood vessels, according to a notice published on the agency's official website in June 2026.
What Is Avacopan?
Avacopan is a medicine used in the management of certain rare autoimmune conditions. These conditions are characterised by inflammation that targets small blood vessels, a category of disease that can be serious and difficult to treat. The drug represents one of a limited number of therapeutic options available for patients with such diagnoses.
About the MHRA Review
Regulatory reviews of this kind are a standard part of post-authorisation pharmacovigilance. The MHRA periodically examines available evidence on medicines already in use to determine whether their established benefits continue to outweigh any identified risks. The agency's assessment of avacopan follows this established process.
The full details of the review's findings, including any specific conclusions or regulatory actions arising from the assessment, are outlined in the MHRA's published notice.
Context for Rare Autoimmune Conditions
Autoimmune diseases affecting small blood vessels are classified as rare, meaning they occur in a relatively small proportion of the population. Because of this, the evidence base for treatments in this area is often more limited than for common conditions, making regulatory scrutiny of available medicines particularly important. Benefit-risk assessments by bodies such as the MHRA help ensure that medicines in active use continue to meet the standards required for patient safety.
The MHRA is the regulatory authority responsible for overseeing the safety, quality, and efficacy of medicines and medical devices in the United Kingdom.